Abingdon Health PLC (GB:ABDX)
LSE:ABDX
ABDX Stock Chart & Stats
6.25 p
0.20 p(2.50%)
At close: 4:00 PM EST
6.25 p
0.20 p(2.50%)
Day’s Range― - ―
52-Week Range5.10 p - 9.00 p
Previous CloseN/A
Volume7.61K
Average Volume (3M)78.74K
Market Cap
£20.09M
Enterprise Value12.73M
Total Cash (Recent Filing)£3.71M
Total Debt (Recent Filing)£948.00K
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Nov 18, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding251,077,850
10 Day Avg. Volume45,332
30 Day Avg. Volume78,736
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.84
Price to Sales (P/S)3.04
P/FCF Ratio-7.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£12.18M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained double-digit revenue growth indicates expanding market adoption of rapid lateral flow tests and growing contract volumes. Over 2-6 months this trend supports a larger, more predictable order book and justifies incremental capacity investment by management to capture continued diagnostic demand.
Contract Manufacturing Business ModelA CDMO-style model for lateral flow immunoassays creates durable, service-driven revenue streams tied to customer development and manufacturing agreements. Long-term contracts and technical know-how generate sticky relationships, helping smooth revenue volatility versus pure product sales.
Manageable LeverageRelatively low leverage preserves financial flexibility to fund capex, facility upgrades, or working capital needs without immediate refinancing pressure. This balance sheet cushion supports multi-quarter scaling of production and absorption of demand seasonality.
Bears Say
Profitability PressurePersistently negative profit and EBIT margins indicate the business is not converting higher revenues into operating profits. Over months this limits internal funding for R&D and capacity, forces trade-offs on pricing or cost cuts, and can delay path to sustainable profitability.
Weak Operating Cash FlowNegative operating cash flow despite FCF growth suggests timing or working-capital issues that impair core cash generation. Reliance on external financing or one-off cash items to fund operations can persist for months, constraining investments and increasing financing cost risk.
Poor Return On EquityA negative ROE signals capital is not delivering shareholder returns and reflects operating inefficiencies or thin margins. Over the medium term this undermines reinvestment economics, may necessitate restructuring, and weakens investor confidence in management's capital allocation.
Abingdon Health PLC News
ABDX FAQ
What was Abingdon Health PLC’s price range in the past 12 months?
Abingdon Health PLC lowest share price was 5.10 p and its highest was 9.00 p in the past 12 months.
What is Abingdon Health PLC’s market cap?
Abingdon Health PLC’s market cap is £20.09M.
When is Abingdon Health PLC’s upcoming earnings report date?
Abingdon Health PLC’s upcoming earnings report date is Nov 18, 2026 which is in 224 days.
How were Abingdon Health PLC’s earnings last quarter?
Abingdon Health PLC released its earnings results on Mar 17, 2026. The company reported -0.004 p earnings per share for the quarter, beating the consensus estimate of -0.006 p by 0.002 p.
Is Abingdon Health PLC overvalued?
According to Wall Street analysts Abingdon Health PLC’s price is currently Overvalued.
Does Abingdon Health PLC pay dividends?
Abingdon Health PLC does not currently pay dividends.
What is Abingdon Health PLC’s EPS estimate?
Abingdon Health PLC’s EPS estimate is <0.01.
How many shares outstanding does Abingdon Health PLC have?
Abingdon Health PLC has 251,077,850 shares outstanding.
What happened to Abingdon Health PLC’s price movement after its last earnings report?
Abingdon Health PLC reported an EPS of -0.004 p in its last earnings report, beating expectations of -0.006 p. Following the earnings report the stock price went down -3.03%.
Which hedge fund is a major shareholder of Abingdon Health PLC?
Currently, no hedge funds are holding shares in GB:ABDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abingdon Health PLC
Abingdon Health PLC (ABDX) is a UK-based company specializing in the development and manufacture of rapid diagnostic tests. The company focuses on providing innovative solutions in the healthcare sector, particularly in the fields of infectious diseases, including COVID-19 testing, and other point-of-care testing applications. Abingdon Health aims to enhance patient outcomes through its high-quality, reliable diagnostics that are designed for use in various settings, ranging from hospitals to home testing.
Technical Analysis
Circassia Pharmaceuticals
―
EKF Diagnostics Holdings
―
Genedrive
―
Omega Diagnostics
―
Renalytix
―
Options Prices
Currently, No data available
---